•
BN
BNTC
Benitec Biopharma Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
410.41M
Volume
80.00K
52W High
$17.15
52W Low
$9.70
Open
$0.00
Prev Close
$11.63
Day Range
0.00 - 0.00
About Benitec Biopharma Inc. Common Stock
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Latest News
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
GlobeNewswire Inc.•Jan 11
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
GlobeNewswire Inc.•Nov 14
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
GlobeNewswire Inc.•Nov 3
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
GlobeNewswire Inc.•Feb 14
RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034
GlobeNewswire Inc.•Feb 10
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
GlobeNewswire Inc.•Oct 12
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
GlobeNewswire Inc.•Sep 26
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
GlobeNewswire Inc.•Sep 18